All In Biotech

Drug Trial Radar · NCT02174731

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis.

A Phase 3, Multicenter, Randomized, Open-label, Active-Controlled Study of the Safety and Efficacy of Roxadustat in the Treatment of Anemia in Dialysis Patients

Last checked: Nov 19, 2026Latest source record: Dec 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,133 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,133

Actual

Start

Jul 1, 2014

Primary completion

Sep 26, 2018

Study completion Sep 26, 2018

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Kyntra Bio
First posted
Jun 25, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of roxadustat compared to epoetin alfa for the treatment of anemia in chronic kidney disease patients on dialysis.

Conditions

  • Anemia

Interventions

  • RoxadustatDrug

    Roxadustat will be administered orally three times a week (TIW) to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.

  • Epoetin alfaDrug

    Epoetin alfa will be administered TIW consistent with approved prescribing information for epoetin alfa to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52Time frame: Baseline (Day 1, Week 0), Week 28 to 52

Locations

188 sites in 18 countries. Site status is shown where the registry gives one.

  • Research Site

    Huntsville, Alabama

  • Research Site

    El Centro, California

  • Research Site

    Fairfield, California

  • Research Site

    Glendale, California

  • Research Site

    Long Beach, California

  • Research Site

    Long Beach, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Lynwood, California

  • Research Site

    Northridge, California

  • Research Site

    Ontario, California

  • Research Site

    Orange, California

  • Research Site

    Riverside, California

  • Research Site

    Sacramento, California

  • Research Site

    Sun Valley, California

  • Research Site

    Whittier, California

  • Research Site

    Whittier, California

  • Research Site

    Denver, Colorado

  • Research Site

    New Haven, Connecticut

  • Research Site

    Miami Gardens, Florida

  • Research Site

    River Forest, Illinois

  • Research Site

    Wichita, Kansas

  • Research Site

    Baton Rouge, Louisiana

  • Research Site

    Lanham, Maryland

  • Research Site

    Plymouth, Massachusetts

  • Research Site

    Roseville, Michigan

  • Research Site

    Gulfport, Mississippi

  • Research Site

    Kansas City, Missouri

  • Research Site

    Reno, Nevada

  • Research Site

    Paterson, New Jersey

  • Research Site

    Great Neck, New York

  • Research Site

    Orchard Park, New York

  • Research Site

    The Bronx, New York

  • Research Site

    Asheville, North Carolina

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Wilmington, North Carolina

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Shawnee, Oklahoma

  • Research Site

    Bethlehem, Pennsylvania

  • Research Site

    Philadelphia, Pennsylvania

Showing 40 of 188 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.